Advanced in Congenital Hyperinsulinism

Dr. Andrea Haqq

Pediatric Endocrinology
Office
2100 Erwin Rd, 
Durham, NC 
Advanced in Congenital Hyperinsulinism
Office
2100 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrea Haqq is a Pediatric Endocrinologist in Durham, North Carolina. Dr. Haqq is rated as an Advanced provider by MediFind in the treatment of Congenital Hyperinsulinism. Her top areas of expertise are Bardet-Biedl Syndrome, Prader-Willi Syndrome, Obesity, Sleeve Gastrectomy, and Islet Cell Transplantation.

Her clinical research consists of co-authoring 86 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles in the study of Congenital Hyperinsulinism.

Specialties
Pediatric Endocrinology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
2100 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2/Phase 3
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 3
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Enrollment Status: Completed
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Enrollment Status: Completed
Publish Date: November 15, 2022
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Involving Variants in Hypothalamic Genes Upstream or Downstream From the Melanocortin-4 Receptor (MC4R)
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Involving Variants in Hypothalamic Genes Upstream or Downstream From the Melanocortin-4 Receptor (MC4R)
Enrollment Status: Completed
Publish Date: May 04, 2021
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: March 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

86 Total Publications

Early-Onset of Obesity Model: Impact of Early-Onset Obesity on Comorbidity Risk and Life Expectancy.
Early-Onset of Obesity Model: Impact of Early-Onset Obesity on Comorbidity Risk and Life Expectancy.
Journal: Obesity facts
Published: May 08, 2025
Similar Doctors
Advanced in Congenital Hyperinsulinism
Dr. Michael Freemark
Pediatric Endocrinology
Advanced in Congenital Hyperinsulinism
Dr. Michael Freemark
Pediatric Endocrinology

Office

3000 Erwin Rd Ste 200, 
Durham, NC 
 (2.6 miles away)
919-684-3772
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Freemark is a Pediatric Endocrinologist in Durham, North Carolina. Dr. Freemark is rated as an Advanced provider by MediFind in the treatment of Congenital Hyperinsulinism. His top areas of expertise are Prader-Willi Syndrome, Obesity, Obesity in Children, and Congenital Hyperinsulinism.

Ihab A. Abdel-Khalek
Advanced in Congenital Hyperinsulinism
Dr. Ihab A. Abdel-Khalek
Pediatrics | Pediatric Endocrinology
Advanced in Congenital Hyperinsulinism
Dr. Ihab A. Abdel-Khalek
Pediatrics | Pediatric Endocrinology

Clayton Pediatric Center

11708 Clayton Blvd, 
Clayton, NC 
 (35.4 miles away)
919-550-2770
Experience:
37+ years
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients

Ihab Abdel-Khalek is a Pediatrics specialist and a Pediatric Endocrinologist in Clayton, North Carolina. Dr. Abdel-Khalek has been practicing medicine for over 37 years and is rated as an Advanced provider by MediFind in the treatment of Congenital Hyperinsulinism. His top areas of expertise are Congenital Hyperinsulinism, Low Blood Sugar, Herpangina, and Type A Insulin Resistance Syndrome. Dr. Abdel-Khalek is currently accepting new patients.

Pinar Gumus
Experienced in Congenital Hyperinsulinism
Dr. Pinar Gumus
Pediatric Endocrinology
Experienced in Congenital Hyperinsulinism
Dr. Pinar Gumus
Pediatric Endocrinology

Duke University Hospital

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-684-3772
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pinar Gumus is a Pediatric Endocrinologist in Durham, North Carolina. Dr. Gumus is rated as an Experienced provider by MediFind in the treatment of Congenital Hyperinsulinism. Her top areas of expertise are Obesity in Children, Congenital Hyperinsulinism, Obesity, and Precocious Puberty.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haqq's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile